← Back to Clinical Trials
Recruiting NCT05457569

NCT05457569 Acceptability and Feasibility of Implementing a Coordinated Hospital/Non-hospital Parenting Support and Prevention Program for Families of Infants at High Neurodevelopmental Risk After Neonatal Intensive Care Hospitalization

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05457569
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire Dijon
Condition Neurodevelopmental Motor Disorders
Study Type OBSERVATIONAL
Enrollment 88 participants
Start Date 2023-01-09
Primary Completion 2025-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Focus group (FC) - WP1Child Neurodevelopment Questionnaires - WP2Evaluation of compliance for the acquired skills in terms of development support - WP2

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 88 participants in total. It began in 2023-01-09 with a primary completion date of 2025-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The PRéPaR project aims to construct, with the help of parents and early care providers, a support program for the families of infants at an increased risk for neurodevelopmental disorders, and to evaluate the acceptability and feasibility of such a program. This program aims to strengthen parenting skills, support infant development and improve the continuity of hospital/non-hospital care, including early identification of neurodevelopmental motor disorders and continuation of the support initiated during neonatal hospitalization.

Eligibility Criteria

Inclusion Criteria: WP1: 1. For the group of parents of children with documented neurodevelopmental difficulties, their child must meet the following three conditions: * Be between 18 months and 48 months corrected age at the time of the first focus group * Have at least one risk factor putting them at high neurodevelopmental risk at birth: * Preterm infant ≤ 31 WG + 6 days * Birth weight less than 1500g * Child who has had a stroke or stages 2 or 3 hypoxic-ischaemic encephalopathy of the newborn according to the Sarnat classification * Central neurological lesion, diagnosed on brain imaging. * Present an abnormal, non-transient clinical state: diagnosis of cerebral palsy made or in progress (GMFCS 1 to 5), central neurological syndrome, diagnosed neurodevelopmental disorder. The parents must be able to participate in the 3 interviews (T1, T2 and T3). 2. For the group of infants at high neurodevelopmental risk at hospital discharge, their child must meet the following two conditions: * Be between 34 weeks of amenorrhea (i.e., 1.5 months premature) and 12 months of corrected age at the time of the first focus group, * Have at least one risk factor putting them at high neurodevelopmental risk at birth: * Preterm infant ≤ 31 WG + 6 days * Birth weight less than 1500g * Child who has had a stroke or stages 2 or 3 hypoxic-ischaemic encephalopathy of the newborn according to the Sarnat classification * Central neurological lesion, diagnosed on brain imaging. The parents must be able to participate in the 3 interviews (T1, T2 and T3). 3. Professionals and parent support groups: Physiotherapists in private practice, labor and delivery nurses of the Maternal and Child Protection, CAMSP (psychomotricians, psychologists) and doctors involved in the care of children at developmental risk in charge of the follow-up of children for whom the parents have agreed to participate in the study. These professionals must in turn have agreed to participate in the study. User representatives (SOS Préma, Le Neurogroup...) who have agreed to participate in the study. WP2: 1. Parents of children hospitalized in the neonatal services of the CHU Dijon who meet at least one of the following criteria: * Be between 34 weeks of amenorrhea (1.5 months premature) and 3 months of corrected age (3 months post-term) * Have at least one risk factor putting them at high neurodevelopmental risk at birth: * Child who has had a stroke or stages 2 or 3 hypoxic-ischaemic encephalopathy of the newborn according to the Sarnat classification * Central neurological lesion, diagnosed on brain imaging. 2. Professionals: Physiotherapists in private practice, labor and delievery nurses of the Maternal and Child Protection, CAMSP (psychomotricians, psychologists) and physicians involved in the care of children at developmental risk in charge of the follow-up of the children whose parents agreed to participate in the study. These professionals must in turn have agreed to participate in the study. Exclusion Criteria: * Parents who are physically or cognitively unable to participate in a group interview or who do not have a sufficient command of French. * Parents who are minors * Parents under legal protection * Parents of children with major orthopedic or traumatic disorders unrelated to the high risk of cerebral palsy.

Contact & Investigator

Central Contact

Sandrine JANDET CARON

✉ sandrine.jandet@gmail.com

📞 0672089035

Frequently Asked Questions

Who can join the NCT05457569 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Neurodevelopmental Motor Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05457569 currently recruiting?

Yes, NCT05457569 is actively recruiting participants. Contact the research team at sandrine.jandet@gmail.com for enrollment information.

Where is the NCT05457569 trial being conducted?

This trial is being conducted at Dijon, France.

Who is sponsoring the NCT05457569 clinical trial?

NCT05457569 is sponsored by Centre Hospitalier Universitaire Dijon. The trial plans to enroll 88 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology